Molecular Imaging — MCQs

Q: A patient with treated breast cancer shows a liver lesion on CT. FDG-PET shows SUVmax of 2.8 in the lesion. Follow-up scan after 3 months shows increase in size but SUVmax decreased to 1.9. What is the most likely explanation?

Treatment-induced necrosis with favorable prognosis. ***Treatment-induced necrosis with favorable prognosis*** - A decrease in **SUVmax** indicates a reduction in **metabolic activity** and viable tumor cells, even if the physical dimensions of the lesion increase. - The increase in size is often due to **necrosis, edema, or inflammation** following successful therapy, representing a favorable response to treatment rather than failure. *Progressive disease requiring treatment escalation* - Progressive disease typically presents with an **increase in both size and SUVmax**, reflecting active metabolic growth of the tumor. - Relying solely on **CT size measurements** (like RECIST criteria) can be misleading when PET shows a significant drop in **glucose metabolism**. *Flare phenomenon indicating treatment response* - The **flare phenomenon** usually refers to a transient *increase* in tracer uptake (SUVmax) shortly after starting treatment (e.g., bone flare in breast cancer patients). - In this scenario, the activity **decreased over 3 months**, which is more consistent with a sustained metabolic response than a metabolic flare. *Infection complicating the metastasis* - An active infection or inflammatory process would typically lead to an **increase in SUVmax** due to high metabolic activity in activated white blood cells. - There is no clinical information provided to suggest systemic **fever or local infection**, and the metabolic trend (decreasing SUV) contradicts an inflammatory spike.

Q: A 58-year-old woman with gastrinoma undergoes both FDG-PET and 68Ga-DOTATATE PET scans. FDG-PET shows minimal uptake (SUVmax 2.1) while DOTATATE scan shows intense uptake (SUVmax 45). What does this pattern indicate about tumor biology?

Well-differentiated slow-growing tumor. ***Well-differentiated slow-growing tumor*** - High **DOTATATE uptake** indicates dense expression of **somatostatin receptors (SSTRs)**, which is a hallmark of well-differentiated neuroendocrine tumors. - Low **FDG uptake** (low SUVmax) reflects a low rate of glucose metabolism, signifying a **low-grade (G1/G2)** tumor with a slow proliferation rate. *High grade aggressive tumor* - Aggressive, high-grade neuroendocrine carcinomas (G3) typically show high **FDG avidity** because they rely heavily on glycolysis for energy. - These tumors often lose their **somatostatin receptor expression**, leading to low or absent uptake on a **DOTATATE scan**. *Necrotic tumor with inflammation* - **Necrosis** generally presents as a photopenic (cold) area in the center of a lesion on PET imaging, not intense DOTATATE uptake. - **Inflammation** would typically result in increased **FDG uptake** due to high metabolic activity in activated leukocytes, rather than isolated high DOTATATE avidity. *False positive DOTATATE scan* - Intense uptake with an **SUVmax of 45** is highly specific for SSTR-rich tissues and is considered diagnostic for neuroendocrine pathology in this clinical context. - A **gastrinoma** is a known neuroendocrine tumor (NET) that consistently expresses these receptors, making a false positive highly unlikely.

Q: A 65-year-old man with known lung cancer undergoes FDG-PET scan. The scan shows intense FDG uptake (SUVmax 8.5) in the primary lung mass and a 1.2 cm mediastinal lymph node with SUVmax 4.2. What is the most appropriate interpretation?

Both primary and nodal metastasis. ***Both primary and nodal metastasis*** - In lung cancer staging, a **Standardized Uptake Value (SUVmax)** greater than 2.5 in mediastinal lymph nodes is highly suspicious for **metastatic involvement**. - The node's SUVmax of 4.2 relative to the primary tumor's high uptake (8.5) strongly indicates **metabolically active disease** at both the primary and nodal sites. *Primary tumor with false positive node* - **False positives** on PET often occur due to granulomatous disease or infection, but an SUVmax of 4.2 in a known cancer context is more likely **metastatic**. - Without history of **sarcoidosis** or active infection, the metabolic activity in the lymphatic basin of the primary tumor is considered malignant until proven otherwise. *Dual primary malignancies* - Two separate primary malignancies would typically involve different anatomical sites or different **histological features**, rather than a primary and its draining node. - The presence of a mediastinal node in a patient with a known lung mass is the classic presentation of **regional spread** (N staging), not a second primary site. *Primary tumor only, node is inflammatory* - While inflammation can cause **FDG avidity**, an SUVmax of 4.2 is significantly high and less typical for purely reactive or **incidental inflammatory** nodes. - Relying on an inflammatory interpretation without biopsy would risk **understaging** the patient's lung cancer, as the node meets the metabolic criteria for malignancy.

Q: How does 68Ga-DOTATATE molecular imaging differ from FDG-PET in mechanism of tumor detection?

It binds to somatostatin receptors. ***It binds to somatostatin receptors*** - **68Ga-DOTATATE** is a radiolabeled somatostatin analogue that specifically targets cells overexpressing **somatostatin receptors (SSTR)**, particularly subtype **SSTR2**. - This receptor-ligand binding allows for highly specific imaging of **neuroendocrine tumors (NETs)**, which is fundamentally different from metabolic pathways. *It targets metabolic activity* - This describes the mechanism of **18F-FDG PET**, which relies on **glucose metabolism** and the upregulation of **GLUT transporters** in malignant cells. - While effective for aggressive cancers, many low-grade neuroendocrine tumors have low metabolic rates and may be **FDG-negative**. *It measures blood flow* - Measuring blood flow is characteristic of certain **perfusion scans** or dynamic contrast-enhanced imaging, not the molecular targeting of DOTATATE. - Radiopharmaceuticals like **15O-water** or certain technetium-based agents are used for perfusion studies rather than receptor-specific mapping. *It detects DNA synthesis* - Agents that detect DNA synthesis, such as **18F-FLT**, target the enzyme **thymidine kinase-1** to visualize cellular proliferation. - While provide information on tumor growth, this is distinct from the **somatostatin receptor expression** targeted by **68Ga-DOTATATE**.

Q: What is the underlying principle behind FDG uptake in malignant cells during PET imaging?

Warburg effect and increased glycolysis. ***Warburg effect and increased glycolysis*** - Malignant cells exhibit the **Warburg effect**, which is characterized by high rates of **glycolysis** and glucose uptake even in the presence of oxygen. - **FDG (Fluorodeoxyglucose)** is a glucose analogue that is transported into cells by **GLUT transporters** and phosphorylated, but it remains trapped as it cannot undergo further metabolism. *Increased fatty acid metabolism* - While some cancers may utilize fatty acids, PET imaging with FDG specifically targets the **glucose metabolic pathway**, not lipid metabolism. - Fatty acid imaging typically requires different radiopharmaceuticals, such as **11C-acetate** or **18F-FCHP**. *Increased DNA synthesis* - Increased DNA synthesis is a hallmark of cellular proliferation but is not the mechanism detected by **FDG-PET scans**. - Radiotracers like **18F-FLT (fluorothymidine)** are used to measure proliferation and DNA synthesis rather than glucose consumption. *Enhanced protein synthesis* - Enhanced protein synthesis reflects the **anabolic state** of a tumor but does not explain the accumulation of glucose analogues. - Amino acid analogues, such as **11C-methionine** or **18F-FET**, are specifically used to image protein synthesis and amino acid transport in oncology.

Q: What is the physical half-life of Fluorine-18 used in PET imaging?

110 minutes. ***110 minutes*** - **Fluorine-18 (F-18)** has a physical half-life of approximately **109.8 minutes**, making it ideal for clinical PET imaging. - This duration is long enough to allow for **radiopharmaceutical synthesis** and distribution, yet short enough to limit the patient's **radiation dose**. *24 hours* - This is much longer than the half-life of common **PET isotopes** and would lead to excessive, unnecessary radiation exposure. - **Indium-111**, used in SPECT imaging, has a longer half-life (approx. **2.8 days**), but is not F-18. *20 minutes* - This describes the half-life of **Carbon-11**, another positron emitter used in PET research. - Isotopes with a **20-minute half-life** require an **on-site cyclotron** because they decay too rapidly for transport between facilities. *6 hours* - This is the physical half-life of **Technetium-99m**, the most widely used isotope in **diagnostic nuclear medicine (SPECT)**. - While **6 hours** is convenient for logistics, it is not associated with the positron emission decay of **Fluorine-18**.

Q: Which radiotracer is most commonly used for FDG-PET imaging in oncology?

18F-Fluorodeoxyglucose. ***18F-Fluorodeoxyglucose*** - **18F-FDG** is a glucose analogue that is taken up by cells via **GLUT transporters** and phosphorylated, but cannot be further metabolized, leading to **metabolic trapping**. - It is the gold standard for oncology PET imaging because malignant cells exhibit **Warburg effect**, showing significantly increased **glucose metabolism** compared to normal tissues. *68Ga-DOTATATE* - This is a specialized radiotracer used specifically for imaging **neuroendocrine tumors** that express **somatostatin receptors**. - It is not used for general oncologic screening as it does not rely on the high glucose demands of typical carcinomas. *99mTc-Sestamibi* - This is primarily used in **SPECT imaging**, not PET, for applications such as **myocardial perfusion** imaging and checking **parathyroid adenomas**. - Unlike FDG, it is a lipophilic cation that localizes in **mitochondria** rather than tracking glucose consumption. *11C-Methionine* - This is an **amino acid tracer** used mainly in **neuro-oncology** to differentiate brain tumor recurrence from radiation necrosis. - Its use is limited in routine clinical practice due to the very short **half-life of Carbon-11** (approximately 20 minutes), requiring an on-site cyclotron.

A research team is developing a new radiotracer for imaging hypoxia in tumors. They need to select between 18F-labeled and 64Cu-labeled versions of the same molecule. Considering half-lives (18F: 110 min, 64Cu: 12.7 hours), positron ranges, and clinical applicability, which choice and rationale is most appropriate?

In designing a clinical protocol for PSMA PET imaging in prostate cancer, which combination of factors would provide optimal image quality while minimizing radiation exposure?

A patient with treated breast cancer shows a liver lesion on CT. FDG-PET shows SUVmax of 2.8 in the lesion. Follow-up scan after 3 months shows increase in size but SUVmax decreased to 1.9. What is the most likely explanation?

A 58-year-old woman with gastrinoma undergoes both FDG-PET and 68Ga-DOTATATE PET scans. FDG-PET shows minimal uptake (SUVmax 2.1) while DOTATATE scan shows intense uptake (SUVmax 45). What does this pattern indicate about tumor biology?

A 45-year-old diabetic patient presents for FDG-PET scan for lymphoma staging. Blood glucose is 220 mg/dL. What is the most appropriate management before proceeding with imaging?

A 65-year-old man with known lung cancer undergoes FDG-PET scan. The scan shows intense FDG uptake (SUVmax 8.5) in the primary lung mass and a 1.2 cm mediastinal lymph node with SUVmax 4.2. What is the most appropriate interpretation?

How does 68Ga-DOTATATE molecular imaging differ from FDG-PET in mechanism of tumor detection?

What is the underlying principle behind FDG uptake in malignant cells during PET imaging?

What is the physical half-life of Fluorine-18 used in PET imaging?

Q10

Which radiotracer is most commonly used for FDG-PET imaging in oncology?

Molecular Imaging Indian Medical PG Practice Questions and MCQs

Question 1: A research team is developing a new radiotracer for imaging hypoxia in tumors. They need to select between 18F-labeled and 64Cu-labeled versions of the same molecule. Considering half-lives (18F: 110 min, 64Cu: 12.7 hours), positron ranges, and clinical applicability, which choice and rationale is most appropriate?

A. 64Cu for longer imaging window despite inferior image quality
B. 64Cu because shorter positron range improves resolution
C. 18F for better spatial resolution despite requiring on-site cyclotron (Correct Answer)
D. 18F because longer half-life allows delayed imaging

Explanation: ***18F for better spatial resolution despite requiring on-site cyclotron*** - **18F** has a shorter **positron range** compared to **64Cu**, which minimizes the distance the positron travels before annihilation, leading to superior **spatial resolution**. - While it necessitates proximity to a **cyclotron** due to a 110-minute half-life, this timeframe is sufficient for most **hypoxia imaging** tracers to reach a high **target-to-background ratio**. *64Cu for longer imaging window despite inferior image quality* - **64Cu** provides a longer imaging window due to its **12.7-hour half-life**, but its longer **positron range** leads to increased **blurring** and poorer resolution. - For diagnostic **tumor hypoxia**, the extra-long window is often unnecessary and leads to a higher **absorbed radiation dose** for the patient. *64Cu because shorter positron range improves resolution* - This statement is factually incorrect as **64Cu** actually has a significantly longer **effective positron range** than **18F**. - Higher **energy positrons** travel further in tissue, which degrades the **image quality** by misplacing the site of annihilation relative to the source. *18F because longer half-life allows delayed imaging* - This is incorrect as **18F** has a much shorter half-life (**110 minutes**) compared to the **12.7 hours** of **64Cu**. - The shorter half-life of **18F** prevents very late delayed imaging but helps in keeping the total **patient radiation exposure** lower.

Question 2: In designing a clinical protocol for PSMA PET imaging in prostate cancer, which combination of factors would provide optimal image quality while minimizing radiation exposure?

A. 18F-PSMA with 4 hour delayed imaging
B. 68Ga-PSMA with 3 hour uptake time without furosemide
C. 68Ga-PSMA with 1 hour uptake time and furosemide administration (Correct Answer)
D. 18F-PSMA with 30 minutes uptake time and forced hydration

Explanation: ***68Ga-PSMA with 1 hour uptake time and furosemide administration*** - An **uptake time of 60 minutes** is the standard for **68Ga-PSMA**, providing an optimal **target-to-background ratio** (TBR) while maintaining efficient clinical workflow. - The administration of **furosemide** (a loop diuretic) promotes **urinary washout** of the tracer, reducing interfering **bladder activity** and lowering the radiation dose to the urinary tract. *18F-PSMA with 4 hour delayed imaging* - While **18F-labeled tracers** have a longer half-life, a 4-hour delay is excessive and leads to significant **decay of activity**, potentially requiring higher initial doses and increasing **radiation exposure**. - Such long delays are not practical for routine clinical protocols and do not provide a significant clinical advantage over standard 1-2 hour imaging for most **PSMA** ligands. *68Ga-PSMA with 3 hour uptake time without furosemide* - **68Ga** has a short physical half-life (68 minutes), so a 3-hour wait significantly reduces the **count rate**, leading to poor **image quality** due to increased noise. - Omitting **furosemide** results in high tracer concentration in the **bladder**, which can obscure local recurrence in the **prostate bed** or nearby pelvic lymph nodes via **halo artifacts**. *18F-PSMA with 30 minutes uptake time and forced hydration* - A **30-minute uptake time** is generally insufficient for optimal **tracer internalization** into prostate cancer cells, resulting in a lower **tumor-to-background ratio**. - Although **forced hydration** helps, it is less effective than **furosemide** at rapidly clearing the high-intensity tracer from the **distal ureters** and bladder during the peak imaging window.

Question 3: A patient with treated breast cancer shows a liver lesion on CT. FDG-PET shows SUVmax of 2.8 in the lesion. Follow-up scan after 3 months shows increase in size but SUVmax decreased to 1.9. What is the most likely explanation?

A. Progressive disease requiring treatment escalation
B. Treatment-induced necrosis with favorable prognosis (Correct Answer)
C. Flare phenomenon indicating treatment response
D. Infection complicating the metastasis

Explanation: ***Treatment-induced necrosis with favorable prognosis*** - A decrease in **SUVmax** indicates a reduction in **metabolic activity** and viable tumor cells, even if the physical dimensions of the lesion increase. - The increase in size is often due to **necrosis, edema, or inflammation** following successful therapy, representing a favorable response to treatment rather than failure. *Progressive disease requiring treatment escalation* - Progressive disease typically presents with an **increase in both size and SUVmax**, reflecting active metabolic growth of the tumor. - Relying solely on **CT size measurements** (like RECIST criteria) can be misleading when PET shows a significant drop in **glucose metabolism**. *Flare phenomenon indicating treatment response* - The **flare phenomenon** usually refers to a transient *increase* in tracer uptake (SUVmax) shortly after starting treatment (e.g., bone flare in breast cancer patients). - In this scenario, the activity **decreased over 3 months**, which is more consistent with a sustained metabolic response than a metabolic flare. *Infection complicating the metastasis* - An active infection or inflammatory process would typically lead to an **increase in SUVmax** due to high metabolic activity in activated white blood cells. - There is no clinical information provided to suggest systemic **fever or local infection**, and the metabolic trend (decreasing SUV) contradicts an inflammatory spike.

Question 4: A 58-year-old woman with gastrinoma undergoes both FDG-PET and 68Ga-DOTATATE PET scans. FDG-PET shows minimal uptake (SUVmax 2.1) while DOTATATE scan shows intense uptake (SUVmax 45). What does this pattern indicate about tumor biology?

A. High grade aggressive tumor
B. Well-differentiated slow-growing tumor (Correct Answer)
C. Necrotic tumor with inflammation
D. False positive DOTATATE scan

Explanation: ***Well-differentiated slow-growing tumor*** - High **DOTATATE uptake** indicates dense expression of **somatostatin receptors (SSTRs)**, which is a hallmark of well-differentiated neuroendocrine tumors. - Low **FDG uptake** (low SUVmax) reflects a low rate of glucose metabolism, signifying a **low-grade (G1/G2)** tumor with a slow proliferation rate. *High grade aggressive tumor* - Aggressive, high-grade neuroendocrine carcinomas (G3) typically show high **FDG avidity** because they rely heavily on glycolysis for energy. - These tumors often lose their **somatostatin receptor expression**, leading to low or absent uptake on a **DOTATATE scan**. *Necrotic tumor with inflammation* - **Necrosis** generally presents as a photopenic (cold) area in the center of a lesion on PET imaging, not intense DOTATATE uptake. - **Inflammation** would typically result in increased **FDG uptake** due to high metabolic activity in activated leukocytes, rather than isolated high DOTATATE avidity. *False positive DOTATATE scan* - Intense uptake with an **SUVmax of 45** is highly specific for SSTR-rich tissues and is considered diagnostic for neuroendocrine pathology in this clinical context. - A **gastrinoma** is a known neuroendocrine tumor (NET) that consistently expresses these receptors, making a false positive highly unlikely.

Question 5: A 45-year-old diabetic patient presents for FDG-PET scan for lymphoma staging. Blood glucose is 220 mg/dL. What is the most appropriate management before proceeding with imaging?

A. Administer insulin and delay scan until glucose <150 mg/dL (Correct Answer)
B. Double the FDG dose to compensate
C. Cancel scan and reschedule after glucose control
D. Proceed immediately with scanning

Explanation: ***Administer insulin and delay scan until glucose <150 mg/dL*** - **Hyperglycemia** causes competitive inhibition of **FDG uptake** in tumor cells, as glucose and FDG compete for the same **GLUT transporters**. - Administering insulin lowers blood glucose to an acceptable range (ideally **<150 mg/dL**) to ensure optimal **diagnostic accuracy** and image quality, though scanning should occur at least 2 hours after insulin administration to avoid muscle uptake. *Double the FDG dose to compensate* - Increasing the **FDG dose** does not bypass the competitive inhibition caused by serum glucose and will only increase **radiation exposure** unnecessarily. - High blood sugar levels will still prioritize **native glucose** over FDG into cells, resulting in a poor **signal-to-noise ratio**. *Cancel scan and reschedule after glucose control* - While long-term control is ideal, acute management with **short-acting insulin** allows the scan to proceed on the same day once levels fall below the threshold. - Rescheduling is only necessary if the patient's **blood glucose** remains persistently high and unresponsive to immediate clinical intervention. *Proceed immediately with scanning* - Scanning with a glucose level of **220 mg/dL** leads to poor image quality and potential **false-negative** results due to diminished tracer uptake in the lymphoma. - Elevated **endogenous glucose** saturates the receptors, preventing the radioactive tracer from adequately labeling the **metabolically active** tumor sites.

Question 6: A 65-year-old man with known lung cancer undergoes FDG-PET scan. The scan shows intense FDG uptake (SUVmax 8.5) in the primary lung mass and a 1.2 cm mediastinal lymph node with SUVmax 4.2. What is the most appropriate interpretation?

A. Both primary and nodal metastasis (Correct Answer)
B. Primary tumor with false positive node
C. Dual primary malignancies
D. Primary tumor only, node is inflammatory

Explanation: ***Both primary and nodal metastasis*** - In lung cancer staging, a **Standardized Uptake Value (SUVmax)** greater than 2.5 in mediastinal lymph nodes is highly suspicious for **metastatic involvement**. - The node's SUVmax of 4.2 relative to the primary tumor's high uptake (8.5) strongly indicates **metabolically active disease** at both the primary and nodal sites. *Primary tumor with false positive node* - **False positives** on PET often occur due to granulomatous disease or infection, but an SUVmax of 4.2 in a known cancer context is more likely **metastatic**. - Without history of **sarcoidosis** or active infection, the metabolic activity in the lymphatic basin of the primary tumor is considered malignant until proven otherwise. *Dual primary malignancies* - Two separate primary malignancies would typically involve different anatomical sites or different **histological features**, rather than a primary and its draining node. - The presence of a mediastinal node in a patient with a known lung mass is the classic presentation of **regional spread** (N staging), not a second primary site. *Primary tumor only, node is inflammatory* - While inflammation can cause **FDG avidity**, an SUVmax of 4.2 is significantly high and less typical for purely reactive or **incidental inflammatory** nodes. - Relying on an inflammatory interpretation without biopsy would risk **understaging** the patient's lung cancer, as the node meets the metabolic criteria for malignancy.

Question 7: How does 68Ga-DOTATATE molecular imaging differ from FDG-PET in mechanism of tumor detection?

A. It targets metabolic activity
B. It binds to somatostatin receptors (Correct Answer)
C. It measures blood flow
D. It detects DNA synthesis

Explanation: ***It binds to somatostatin receptors*** - **68Ga-DOTATATE** is a radiolabeled somatostatin analogue that specifically targets cells overexpressing **somatostatin receptors (SSTR)**, particularly subtype **SSTR2**. - This receptor-ligand binding allows for highly specific imaging of **neuroendocrine tumors (NETs)**, which is fundamentally different from metabolic pathways. *It targets metabolic activity* - This describes the mechanism of **18F-FDG PET**, which relies on **glucose metabolism** and the upregulation of **GLUT transporters** in malignant cells. - While effective for aggressive cancers, many low-grade neuroendocrine tumors have low metabolic rates and may be **FDG-negative**. *It measures blood flow* - Measuring blood flow is characteristic of certain **perfusion scans** or dynamic contrast-enhanced imaging, not the molecular targeting of DOTATATE. - Radiopharmaceuticals like **15O-water** or certain technetium-based agents are used for perfusion studies rather than receptor-specific mapping. *It detects DNA synthesis* - Agents that detect DNA synthesis, such as **18F-FLT**, target the enzyme **thymidine kinase-1** to visualize cellular proliferation. - While provide information on tumor growth, this is distinct from the **somatostatin receptor expression** targeted by **68Ga-DOTATATE**.

Question 8: What is the underlying principle behind FDG uptake in malignant cells during PET imaging?

A. Warburg effect and increased glycolysis (Correct Answer)
B. Increased fatty acid metabolism
C. Increased DNA synthesis
D. Enhanced protein synthesis

Explanation: ***Warburg effect and increased glycolysis*** - Malignant cells exhibit the **Warburg effect**, which is characterized by high rates of **glycolysis** and glucose uptake even in the presence of oxygen. - **FDG (Fluorodeoxyglucose)** is a glucose analogue that is transported into cells by **GLUT transporters** and phosphorylated, but it remains trapped as it cannot undergo further metabolism. *Increased fatty acid metabolism* - While some cancers may utilize fatty acids, PET imaging with FDG specifically targets the **glucose metabolic pathway**, not lipid metabolism. - Fatty acid imaging typically requires different radiopharmaceuticals, such as **11C-acetate** or **18F-FCHP**. *Increased DNA synthesis* - Increased DNA synthesis is a hallmark of cellular proliferation but is not the mechanism detected by **FDG-PET scans**. - Radiotracers like **18F-FLT (fluorothymidine)** are used to measure proliferation and DNA synthesis rather than glucose consumption. *Enhanced protein synthesis* - Enhanced protein synthesis reflects the **anabolic state** of a tumor but does not explain the accumulation of glucose analogues. - Amino acid analogues, such as **11C-methionine** or **18F-FET**, are specifically used to image protein synthesis and amino acid transport in oncology.

Question 9: What is the physical half-life of Fluorine-18 used in PET imaging?

A. 24 hours
B. 110 minutes (Correct Answer)
C. 20 minutes
D. 6 hours

Explanation: ***110 minutes*** - **Fluorine-18 (F-18)** has a physical half-life of approximately **109.8 minutes**, making it ideal for clinical PET imaging. - This duration is long enough to allow for **radiopharmaceutical synthesis** and distribution, yet short enough to limit the patient's **radiation dose**. *24 hours* - This is much longer than the half-life of common **PET isotopes** and would lead to excessive, unnecessary radiation exposure. - **Indium-111**, used in SPECT imaging, has a longer half-life (approx. **2.8 days**), but is not F-18. *20 minutes* - This describes the half-life of **Carbon-11**, another positron emitter used in PET research. - Isotopes with a **20-minute half-life** require an **on-site cyclotron** because they decay too rapidly for transport between facilities. *6 hours* - This is the physical half-life of **Technetium-99m**, the most widely used isotope in **diagnostic nuclear medicine (SPECT)**. - While **6 hours** is convenient for logistics, it is not associated with the positron emission decay of **Fluorine-18**.

Question 10: Which radiotracer is most commonly used for FDG-PET imaging in oncology?

A. 18F-Fluorodeoxyglucose (Correct Answer)
B. 68Ga-DOTATATE
C. 99mTc-Sestamibi
D. 11C-Methionine

Explanation: ***18F-Fluorodeoxyglucose*** - **18F-FDG** is a glucose analogue that is taken up by cells via **GLUT transporters** and phosphorylated, but cannot be further metabolized, leading to **metabolic trapping**. - It is the gold standard for oncology PET imaging because malignant cells exhibit **Warburg effect**, showing significantly increased **glucose metabolism** compared to normal tissues. *68Ga-DOTATATE* - This is a specialized radiotracer used specifically for imaging **neuroendocrine tumors** that express **somatostatin receptors**. - It is not used for general oncologic screening as it does not rely on the high glucose demands of typical carcinomas. *99mTc-Sestamibi* - This is primarily used in **SPECT imaging**, not PET, for applications such as **myocardial perfusion** imaging and checking **parathyroid adenomas**. - Unlike FDG, it is a lipophilic cation that localizes in **mitochondria** rather than tracking glucose consumption. *11C-Methionine* - This is an **amino acid tracer** used mainly in **neuro-oncology** to differentiate brain tumor recurrence from radiation necrosis. - Its use is limited in routine clinical practice due to the very short **half-life of Carbon-11** (approximately 20 minutes), requiring an on-site cyclotron.

Practice by Chapter

Principles of Molecular Imaging

Practice Questions

Radiopharmaceuticals for Molecular Imaging

Practice Questions

PET Radiochemistry

Practice Questions

Molecular Imaging in Oncology

Practice Questions

Molecular Imaging in Cardiology

Practice Questions

Molecular Imaging in Neurology

Practice Questions

Molecular Imaging in Inflammation and Infection

Practice Questions

Reporter Gene Imaging

Practice Questions

Cell Tracking and Imaging

Practice Questions

Nanoparticles in Molecular Imaging

Practice Questions

Theranostics

Practice Questions

Future Directions in Molecular Imaging

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free